Accumulating evidence have indicated that regulatory T cells (Tregs) play an essential role in T cell-mediated immune response and development of multiple myeloma (MM). CD4+FoxP3+ T cells are composed of three phenotypically and functionally distinct subpopulations: CD45RA+FoxP3lo resting Tregs (rTregs), CD45RA−FoxP3hi activated Tregs (aTregs) and CD45RA−FoxP3lo non-suppressive T cells (non-Tregs). We aimed to clarify the frequency and function of these three subpopulations in newly diagnosed multiple myeloma and monoclonal gammopathy of undetermined significance (MGUS) patients. In addition, CD28−CD4+FoxP3+ Treg-like cell is a senescent regulatory T cell subset with partial suppressive function, which could be impaired during myelomagenesis. we examined 20 patients with MGUS, 26 patients with newly diagnosed MM and 18 healthy volunteers. Flow cytometric analysis in peripheral blood and bone marrow was performed for frequency study. The immunosuppressive function of Treg subsets was assessed by their ability to suppress the proliferation of responder cells in co-culture. Concentration of cytokine from the culture supernatants of proliferation assay was measured using ELISA. The proportion of activated Tregs in CD4+ T cells was significantly higher in MGUS and MM patients than healthy controls (P = 0.01, P < 0.001) in both PB and BM; while the proportion of rTregs in MGUS, MM patients was significantly lower than that of controls (P = 0.02, P < 0.01) only in BM. There was no significant difference in frequencies of non-Tregs from MGUS to MM patients with normal controls (P = 0.14, P = 0.88). Significant increase in PB and BM Treg-like cells was observed in MGUS and MM cohort compared with healthy controls (P < 0.01, P < 0.01). Treg-like cells in MM patients were significantly higher than those in MGUS patients (P < 0.01). The inhibition rate of aTreg in bone marrow of MM patients was significantly higher than that of rTreg (P < 0.01), while the inhibition rate of non-Treg was significantly lower than that of rTreg cells (P < 0.01). Functional assays revealed the suppressive and secretory abilities of three Treg subsets were intact in MM patients. In summary, aTregs and aging Treg-like cells were quantitatively altered in MGUS and MM patients, which might be associated with disease progression and prognosis.
Dear Editor, Monoclonal gammopathy of undetermined significance (MGUS) is a clinically asymptomatic premalignant plasma cell disorder, which may develop to multiple myeloma (MM), light-chain amyloidosis, Waldenstrom macroglobulinemia, or other related malignancies 1. The crude prevalence of MGUS varies from 0.05% to 6.1% among distinct population from different countries, which is influenced by race, age, sex, family history, immunosuppression, and pesticide exposure 2. So far, many population-based studies of MGUS come from the white or black population living in Western and African countries. One of the largest population-based study in the USA showed that the prevalence of MGUS was 3.2% in the Caucasian general population aged ≥50 years 3 , while the rate was even higher in African-Americans to be 3.7% 4. However, data on the epidemiology of MGUS remain largely undefined in Asians. Some populationbased studies among population from Thailand, Korea, and Hong Kong were relatively limited due to small sample sizes 5-7. Therefore, we conducted this study to determine the prevalence and characteristics of MGUS among a large population with annual medical checkups in a well-defined geographic area in China.
(2019). Successful treatment of central nervous system involved Erdheim–Chester disease by intermediate-dose cytarabine as first-line therapy. Acta Oncologica. Ahead of Print.
21 August 2025 in Therapeutic Advances in Medical Oncology
Background: Patients with multiple myeloma (MM) and renal impairment (RI), particularly those requiring dialysis, have historically experienced poor outcomes. Despite advancements in targeted therapies, the prognosis of dialysis-dependent MM and factors influencing dialysis independence remain unclear. Objectives: This study aimed to provide a comprehensive analysis of the clinical manifestations and treatment outcomes of dialysis-dependent MM patients in China, and to explore the factors associated with dialysis independence and long-term survival. Design: We conducted a multicenter, retrospective, real-world cohort study. Methods: This multicenter, retrospective study included 122 MM patients requiring chronic hemodialysis (⩾28 days of treatment) at 4 comprehensive hospitals in China from January 2012 to November 2023. Hemodialysis resulting from causes other than MM was excluded. Logistic regression was employed for multivariate analysis of factors associated with dialysis independence, and Kaplan–Meier survival curves and Cox proportional hazard models were utilized for survival analysis. Results: Among the 122 patients, 74 patients (60.7%) were male, with a median age of 65 (39–87) years. Of these, 71.3% ( n = 87) had newly diagnosed MM (NDMM), and 28.7% ( n = 35) had relapsed/refractory MM (RRMM). Dialysis independence was achieved in 27 patients (22 with NDMM and 5 with RRMM). Proteasome inhibitors were used in 80.3% of patients ( n = 98), while 13.9% ( n = 17) received daratumumab-based regimens. After a median follow-up of 43.7 months, the median progression-free survival (PFS) was 14.4 months (95% confidence interval (CI): 3.6–25.2), and the median overall survival (OS) was 27.4 months (95% CI: 6.9–47.9). Dialysis-independent patients had significantly longer PFS (36.7 vs 9.4 months, p = 0.006) and OS (62.6 vs 17.7 months, p < 0.001). Factors associated with dialysis independence included achieving a very good partial response (VGPR), receiving daratumumab-based regimens, reduction in serum-free light chain ⩾80% after the first chemotherapy cycle, and age <65 years. Conclusion: In the era of new drugs, dialysis-dependent MM still has a poor prognosis, although dialysis independence improves survival.